.svg){kind=small}
We are pleased to announce that Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions from 5th to 8th September in Chicago, Illinois.
This event, hosted by the American Heart Association, brings together leading experts to discuss the latest research and advancements in hypertension.
The conference features oral and poster presentations, panel discussions, and sessions tailored for clinicians, researchers, and primary care providers.
To connect with Dr. Taubel during the event, please reach out to arrange a meeting.
Tofind out more, click here.
.png)
-min.jpg)
.jpg)
Latest news
Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease
June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read moreA first of a kind trial in the fight against malaria
June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read moreEvents
AHA Hypertension Scientific Sessions 2024
5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event
